A child with prostaglandin I2-associated thyrotoxicosis: Case report

Yuri Sonoda, Kenichiro Yamamura, Kanako Ishii, Kazuhiro Ohkubo, Kenji Ihara, Yasunari Sakai, Shouichi Ohga

Research output: Contribution to journalArticle

Abstract

Prostaglandin I2 (PGI2) causes hyperthyroidism, a critical complication in patients with pulmonary arterial hypertension (PAH). However, it remains unknown whether PGI2 may have unfavorable effects on thyroid function in children with congenital portosystemic venous shunt syndrome (CPSVS). We present a boy with CPSVS who developed PAH at seven years of age. During ongoing PGI2 therapy, he experienced thyrotoxicosis at 17 years of age. The literature review showed that the reported 12 patients with PAH (median 11 years of age) developed hyperthyroidism during between one and 11 years of PGI2 treatment. Only one patient survived the acute PAH crisis due to hyperthyroidism. These data provide evidence that prophylactic intervention for hyperthyroidism is indicated for children with CPSVS during PGI2 treatment.

Original languageEnglish
Pages (from-to)207-210
Number of pages4
JournalJCRPE Journal of Clinical Research in Pediatric Endocrinology
Volume11
Issue number2
DOIs
Publication statusPublished - Jun 2019

Fingerprint

Thyrotoxicosis
Epoprostenol
Hyperthyroidism
Pulmonary Hypertension
Thyroid Gland
Therapeutics
Patent Ductus Venosus

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

A child with prostaglandin I2-associated thyrotoxicosis : Case report. / Sonoda, Yuri; Yamamura, Kenichiro; Ishii, Kanako; Ohkubo, Kazuhiro; Ihara, Kenji; Sakai, Yasunari; Ohga, Shouichi.

In: JCRPE Journal of Clinical Research in Pediatric Endocrinology, Vol. 11, No. 2, 06.2019, p. 207-210.

Research output: Contribution to journalArticle

Sonoda, Yuri ; Yamamura, Kenichiro ; Ishii, Kanako ; Ohkubo, Kazuhiro ; Ihara, Kenji ; Sakai, Yasunari ; Ohga, Shouichi. / A child with prostaglandin I2-associated thyrotoxicosis : Case report. In: JCRPE Journal of Clinical Research in Pediatric Endocrinology. 2019 ; Vol. 11, No. 2. pp. 207-210.
@article{5d7eaa7048d84380ba41120b5acfb9c9,
title = "A child with prostaglandin I2-associated thyrotoxicosis: Case report",
abstract = "Prostaglandin I2 (PGI2) causes hyperthyroidism, a critical complication in patients with pulmonary arterial hypertension (PAH). However, it remains unknown whether PGI2 may have unfavorable effects on thyroid function in children with congenital portosystemic venous shunt syndrome (CPSVS). We present a boy with CPSVS who developed PAH at seven years of age. During ongoing PGI2 therapy, he experienced thyrotoxicosis at 17 years of age. The literature review showed that the reported 12 patients with PAH (median 11 years of age) developed hyperthyroidism during between one and 11 years of PGI2 treatment. Only one patient survived the acute PAH crisis due to hyperthyroidism. These data provide evidence that prophylactic intervention for hyperthyroidism is indicated for children with CPSVS during PGI2 treatment.",
author = "Yuri Sonoda and Kenichiro Yamamura and Kanako Ishii and Kazuhiro Ohkubo and Kenji Ihara and Yasunari Sakai and Shouichi Ohga",
year = "2019",
month = "6",
doi = "10.4274/jcrpe.galenos.2018.2018.0169",
language = "English",
volume = "11",
pages = "207--210",
journal = "JCRPE Journal of Clinical Research in Pediatric Endocrinology",
issn = "1308-5727",
publisher = "Galenos Yayincilik",
number = "2",

}

TY - JOUR

T1 - A child with prostaglandin I2-associated thyrotoxicosis

T2 - Case report

AU - Sonoda, Yuri

AU - Yamamura, Kenichiro

AU - Ishii, Kanako

AU - Ohkubo, Kazuhiro

AU - Ihara, Kenji

AU - Sakai, Yasunari

AU - Ohga, Shouichi

PY - 2019/6

Y1 - 2019/6

N2 - Prostaglandin I2 (PGI2) causes hyperthyroidism, a critical complication in patients with pulmonary arterial hypertension (PAH). However, it remains unknown whether PGI2 may have unfavorable effects on thyroid function in children with congenital portosystemic venous shunt syndrome (CPSVS). We present a boy with CPSVS who developed PAH at seven years of age. During ongoing PGI2 therapy, he experienced thyrotoxicosis at 17 years of age. The literature review showed that the reported 12 patients with PAH (median 11 years of age) developed hyperthyroidism during between one and 11 years of PGI2 treatment. Only one patient survived the acute PAH crisis due to hyperthyroidism. These data provide evidence that prophylactic intervention for hyperthyroidism is indicated for children with CPSVS during PGI2 treatment.

AB - Prostaglandin I2 (PGI2) causes hyperthyroidism, a critical complication in patients with pulmonary arterial hypertension (PAH). However, it remains unknown whether PGI2 may have unfavorable effects on thyroid function in children with congenital portosystemic venous shunt syndrome (CPSVS). We present a boy with CPSVS who developed PAH at seven years of age. During ongoing PGI2 therapy, he experienced thyrotoxicosis at 17 years of age. The literature review showed that the reported 12 patients with PAH (median 11 years of age) developed hyperthyroidism during between one and 11 years of PGI2 treatment. Only one patient survived the acute PAH crisis due to hyperthyroidism. These data provide evidence that prophylactic intervention for hyperthyroidism is indicated for children with CPSVS during PGI2 treatment.

UR - http://www.scopus.com/inward/record.url?scp=85067308060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067308060&partnerID=8YFLogxK

U2 - 10.4274/jcrpe.galenos.2018.2018.0169

DO - 10.4274/jcrpe.galenos.2018.2018.0169

M3 - Article

C2 - 30325337

AN - SCOPUS:85067308060

VL - 11

SP - 207

EP - 210

JO - JCRPE Journal of Clinical Research in Pediatric Endocrinology

JF - JCRPE Journal of Clinical Research in Pediatric Endocrinology

SN - 1308-5727

IS - 2

ER -